Does osteoporosis therapy invalidate FRAX for fracture prediction?

• Ten-year fracture risk assessment with the fracture risk assessment system (FRAX) is increasingly used to guide treatment decisions. Osteoporosis pharmacotherapy reduces fracture risk, but the effect is greater than can be explained from the increase in bone mineral density (BMD). Whether this invalidates fracture predictions with FRAX is uncertain. A total of 35,764 women (age ≥50 years) and baseline BMD testing (1996–2007) had FRAX probabilities retroactively calculated. A provincial pharmacy database was used to identify osteoporosis medication use. Women were categorized as untreated, current high adherence users [medication possession ratio (MPR) ≥0.80 in the year after BMD testing], current low adherence users (MPR

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

epidemiology

Canada

diagnosis

epidemiology

Aged

Area Under Curve

diagnosis

Risk Assessment

Osteoporotic Fractures

ROC Curve

epidemiology

Humans

Proportional Hazards Models

therapy

Middle Aged

Femoral Neck Fractures

methods

Female

Cohort Studies

Reproducibility of Results

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)